Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/19119
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Atkinson, Victoria | - |
dc.contributor.author | Long, Georgina V | - |
dc.contributor.author | Menzies, Alexander M | - |
dc.contributor.author | McArthur, Grant | - |
dc.contributor.author | Carlino, Matteo S | - |
dc.contributor.author | Millward, Michael | - |
dc.contributor.author | Roberts-Thomson, Rachel | - |
dc.contributor.author | Brady, Benjamin | - |
dc.contributor.author | Kefford, Richard | - |
dc.contributor.author | Haydon, Andrew | - |
dc.contributor.author | Cebon, Jonathan S | - |
dc.date.accessioned | 2018-09-13T00:21:04Z | - |
dc.date.available | 2018-09-13T00:21:04Z | - |
dc.date.issued | 2016-12 | - |
dc.identifier.citation | Asia-Pacific journal of clinical oncology 2016; 12 Suppl 7: 5-12 | - |
dc.identifier.uri | https://ahro.austin.org.au/austinjspui/handle/1/19119 | - |
dc.description.abstract | BRAF mutations occur commonly in metastatic melanomas and inhibition of mutant BRAF and the downstream kinase MEK results in rapid tumor regression and prolonged survival in patients. Combined therapy with BRAF and MEK inhibition improves response rate, progression free survival and overall survival compared with single agent BRAF inhibition, and reduces the skin toxicity that is seen with BRAF inhibitor monotherapy. However, this combination is associated with an increase in other toxicities, particularly drug-related pyrexia, which affects approximately 50% of patients treated with dabrafenib and trametinib (CombiDT). We provide guidance on managing adverse events likely to arise during treatment with combination BRAF and MEK inhibition with CombiDT: pyrexia, skin conditions, fatigue; and discuss management of CombiDT during surgery and radiotherapy. By improving tolerability and in particular preventing unnecessary treatment cessations or reduction in drug exposure, best outcomes can be achieved for patients undergoing CombiDT therapy. | - |
dc.language.iso | eng | - |
dc.subject | BRAF | - |
dc.subject | MEK | - |
dc.subject | dabrafenib | - |
dc.subject | Melanoma | - |
dc.subject | pyrexia | - |
dc.subject | trametinib | - |
dc.title | Optimizing combination dabrafenib and trametinib therapy in BRAF mutation-positive advanced melanoma patients: Guidelines from Australian melanoma medical oncologists. | - |
dc.type | Journal Article | - |
dc.identifier.journaltitle | Asia-Pacific journal of clinical oncology | - |
dc.identifier.affiliation | Olivia Newton-John Cancer Wellness and Research Centre, Austin Health, Heidelberg, Victoria, Australia | en |
dc.identifier.affiliation | Westmead Hospital and Macquarie University, Sydney, New South Wales, Australia | en |
dc.identifier.affiliation | The Alfred Hospital, Melbourne, Victoria, Australia | en |
dc.identifier.affiliation | Princess Alexandra Hospital, Greenslopes Private Hospital and University of Queensland, Brisbane, Queensland, Australia | en |
dc.identifier.affiliation | Melanoma Institute Australia, Royal North Shore and Mater Hospitals, The University of Sydney, Sydney, New South Wales, Australia | en |
dc.identifier.affiliation | Peter MacCallum Cancer Centre and Cabrini Health, Melbourne, Victoria, Australia | en |
dc.identifier.affiliation | Westmead Hospital, Sydney, New South Wales, Australia | en |
dc.identifier.affiliation | School of Medicine and Pharmacology, University of Western Australia, Australia and Sir Charles Gairdner Hospital, Perth, Western Australia, Australia | en |
dc.identifier.affiliation | Queen Elizabeth Hospital, Adelaide, South Australia | en |
dc.identifier.doi | 10.1111/ajco.12656 | - |
dc.identifier.orcid | 0000-0002-3898-950X | - |
dc.identifier.pubmedid | 27905182 | - |
dc.type.austin | Journal Article | - |
local.name.researcher | Cebon, Jonathan S | |
item.languageiso639-1 | en | - |
item.fulltext | No Fulltext | - |
item.grantfulltext | none | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.cerifentitytype | Publications | - |
item.openairetype | Journal Article | - |
crisitem.author.dept | Olivia Newton-John Cancer Research Institute | - |
Appears in Collections: | Journal articles |
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.